Dou Jian-Ping, Yu Jie, Yang Xiao-Huan, Cheng Zhi-Gang, Han Zhi-Yu, Liu Fang-Yi, Yu Xiao-Ling, Liang Ping
Department of Interventional Ultrasound, Chinese People's Liberation Army (PLA) General Hospital, Beijing, 100853, China.
Oncotarget. 2017 Apr 25;8(17):28758-28768. doi: 10.18632/oncotarget.15672.
The aim of this study was to retrospectively compare the long-term efficacy of MW ablation as a curative therapy for hepatocellular carcinoma(HCC) adjacent to large vessels(≥3 mm) with that in safe location. Between 2010 and 2016, 406 patients diagnosed with early-stage HCC at Chinese PLA general hospital were enrolled. One-to-one matched pairs between the vessel group and the safe group were generated using propensity score matching. The associations of treatment strategy with overall survival and local tumor progression were determined by Cox regression. Before matching, 113 patients were classified into the vessel group and 293 patients were classified into the vessel group. The patients in the vessel group were more frequently classified as larger tumor size (P<0.05) and higher AFP level (P<0.05) than patients in the safe group. After propensity score matching, 113 pairs of well-matched HCC patients were selected from different treatment groups. No significant differences were found in local tumor progression, overall survival and complication rates for MW ablation as a first-line treatment for the early-stage HCC between two groups. In conclusion, MW ablation provides an effective and safe way to treat early-stage HCC adjacent to large vessels.
本研究的目的是回顾性比较微波消融作为一种根治性疗法治疗与大血管（≥3mm）相邻的肝细胞癌（HCC）和治疗位于安全位置的HCC的长期疗效。2010年至2016年，中国人民解放军总医院收治的406例早期HCC患者被纳入研究。采用倾向评分匹配法在血管组和安全组之间生成一对一匹配对。通过Cox回归确定治疗策略与总生存期和局部肿瘤进展的相关性。匹配前，113例患者被归入血管组，293例患者被归入安全组。与安全组患者相比，血管组患者的肿瘤大小更大（P<0.05）、甲胎蛋白水平更高（P<0.05）。倾向评分匹配后，从不同治疗组中选出113对匹配良好的HCC患者。两组间微波消融作为早期HCC一线治疗的局部肿瘤进展、总生存期和并发症发生率均无显著差异。总之，微波消融提供了一种有效且安全的方法来治疗与大血管相邻的早期HCC。
